Pavlo Kot

TSHA-102 clinical progress in Rett syndrome highlighted by Taysha Gene Therapies

TSHA-102 clinical progress in Rett syndrome highlighted by Taysha Gene Therapies
Taysha reports TSHA-102 progress

Taysha Gene Therapies has provided an update on its TSHA-102 program, which is currently under clinical evaluation for Rett syndrome. The announcement was made following the company's participation at the 55th Child Neurology Society Annual Meeting.

The company used the event as a forum to share recent developments and connect with clinicians, researchers, and advocates in the pediatric neurology community.

Taysha Gene Therapies has earlier discussed clinical advancements of its TSHA-102 gene therapy at the CNSAM event with the neurology community, as reported here. The company also featured multiple encore presentations on TSHA-102 for Rett syndrome at the Child Neurology Society Annual Meeting, according to previous coverage. These activities highlight ongoing engagement with clinicians and researchers on TSHA-102’s clinical progress.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.